Sa2049 One Third of Patients Treated With Adalimumab or Infliximab for Crohn's Disease or Ulcerative Colitis Permanently Dose-Escalate Due to Loss of Response

✍ Scribed by Fedorak, Darryl K.; Osatiuk, Pam; Wong, Karen; Kroeker, Karen I.; Dieleman, Levinus A.; Fedorak, Richard N.

• Book ID: 122104130
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 174 KB
• Volume: 142
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/S0016-5085(12)61475-9